Investigating biomarkers for treating severe brain injuries with hyperbaric oxygen therapy
Biomarkers in the Hyperbaric Oxygen in Brain Injury Treatment Trial
This study is looking at ways to help patients with severe brain injuries who aren't responding by finding specific markers in their bodies that can show how well they are doing with a special treatment called hyperbaric oxygen therapy, which might improve their recovery.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project ID | NIH-10480031 on NIH RePORTER |
What this research studies
This research focuses on patients with severe traumatic brain injury (TBI) who are unresponsive and require intensive care. The study aims to identify biomarkers that can help monitor patient responses to hyperbaric oxygen therapy, a treatment that may improve outcomes for these individuals. By using biomarkers like glial fibrillary acidic protein (GFAP) and high sensitivity C-reactive protein (hsCRP), the research seeks to personalize treatment and enhance the efficiency of clinical trials. This approach could lead to better-targeted therapies for patients suffering from severe TBI.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with severe TBI, particularly those with a Glasgow Coma Scale score of less than 8.
Not a fit: Patients with mild TBI or those who are not in a prolonged unresponsive state may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment outcomes for patients with severe traumatic brain injuries.
How similar studies have performed: Previous research has shown promise in using biomarkers for monitoring and predicting outcomes in severe TBI, suggesting that this approach could be effective.
Where this research is happening
Ann Arbor, United States
- University of Michigan at Ann Arbor — Ann Arbor, United States (Active)
Researchers
- Principal investigator: Korley, Frederick Kofi — University of Michigan at Ann Arbor
- Study coordinator: Korley, Frederick Kofi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.